Paratek Pharmaceuticals, Inc.

Report azionario NasdaqGM:PRTK

Capitalizzazione di mercato: US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals Gestione

Criteri Gestione verificati 3/4

Paratek Pharmaceuticals Il CEO è Evan Loh, nominato in Jun2019, e ha un mandato di 4.25 anni. la retribuzione annua totale è $ 2.04M, composta da 31.8% di stipendio e 68.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.87% delle azioni della società, per un valore di $ 2.38M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 8.9 anni.

Informazioni chiave

Evan Loh

Amministratore delegato

US$2.0m

Compenso totale

Percentuale dello stipendio del CEO31.82%
Mandato del CEO4.3yrs
Proprietà del CEO1.9%
Durata media del management4.3yrs
Durata media del Consiglio di amministrazione8.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Apr 17

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) shares have had a really impressive month, gaining 77% after a shaky...
Seeking Alpha • Aug 24

Paratek Pharmaceuticals: Patience Is Wearing Thin

Summary Today, we put Paratek Pharmaceuticals in the spotlight for the first time since the early fall of last year. Paratek is advancing its flagship product NUZYRA nicely, but shareholders have not been rewarded to this point in time even as the shares have strong analyst support. What lies ahead for Paratek? An investment analysis follows in the paragraphs below. If you must speak ill of another, do not speak it, write it in the sand near the water's edge. ― Napoleon Hill Today, we are circling back on Paratek Pharmaceuticals (PRTK) for the first time since we posted this piece on this small antibiotic concern back in October of last year. Even as the company has demonstrated solid revenue growth, shareholders have not been rewarded in this name over the past year and patience is starting to wear thin. We update our investment thesis around Paratek Pharmaceuticals via the analysis below. Seeking Alpha Company Overview Paratek Pharmaceuticals is a Boston based antibiotic concern. The company's primary asset is NUZYRA. This is a once-daily oral and intravenous broad-spectrum antibiotic approved for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. The stock sells for around $2.75 a share and sports an approximate market cap of just under $150 million. August Company Presentation The company has some earlier stage candidates in its pipeline. None of them of note to this analysis given they are early in development. The company is advancing NUZYRA in Phase 2 development for Non-Tuberculous Mycobacteria or NTM for which it has Orphan Drug and Fast Track designations from the FDA. August Company Presentation Second Quarter Results On August 3rd, the company posted second quarter numbers. Paratek posted a GAAP loss of 33 cents a share, just a tad above the consensus. Net revenue for the second quarter of 2022 was $29.6 million. This compares to $19.6 million in 2Q2021 when excluding the first procurement of NUZYRA under the BARDA contract of $37.9 million (more detail on that contract in the last section of this article). August Company Presentation The $29.6 million in sales for the quarter included $25.1 million of revenues from NUZYRA's core commercial business. This was up from $14.9 million from the same period a year ago. The company also booked $4 million in sales from the BARDA contract and $600,000 in royalty revenue from SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. August Company Presentation Analyst Commentary & Balance Sheet Only three analyst firms have chimed in around Paratek so far in 2022. On February 10th, WBB Securities upgraded the shares to a Strong Buy with a $11 price target as the analyst there believes 'Nuzyra is a critically important antibiotic that has anchored the franchise'. This month BTIG ($30 price target) and H.C. Wainwright ($20 price target) both maintained their Buy ratings on the stock. Just under 10% of the outstanding float is currently held short. Four insiders sold just over $300,000 worth of shares collectively in August. That has been the only insider activity in the equity so far in 2022. The company ended the first half of this year with nearly $70 million in cash and marketable securities on its balance sheet. Management stated within its second quarter earnings press release that: Based upon the company's current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4 million as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even. August Company Presentation Verdict The current analyst consensus has the company losing a bit over 80 cents a share in FY2022 as revenues rise in the mid teens to some $150 million. Projections from three analyst firms that have provided estimates for FY2023 are in wide range both for earnings (A 42 cent a share loss to profits of $1.37 a share) and revenues ($195 million to $315 million).
Seeking Alpha • Aug 03

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Paratek Pharmaceuticals press release (NASDAQ:PRTK): Q2 GAAP EPS of -$0.33 beats by $0.01. Revenue of $29.6M (-48.5% Y/Y) beats by $0.42M. Based upon the company’s current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4M as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even.
Seeking Alpha • Jan 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

2021 revenue estimate: $128-139 million; 2022 revenue estimate: $200 million. Revenue estimates for CABP and ABSSSI near $400 million by 2028; NTM could generate even higher sales well into the 2030s. $304 million BARDA contract (2019-2023) provides a pathway to profitability by 4Q2022. Deeply undervalued: enterprise value of $369 million is less than 2X 2022 sales.
Seeking Alpha • Oct 18

The Play On Paratek Pharmaceuticals

Today, we take a quick look back at antibiotic concern Paratek Pharmaceuticals. While I am very underweight the antibiotic space due to the terrible economics there, Paratek has some unique features that make the stock one I own. An analysis and how I am positioned in Paratek Pharmaceuticals follows in the paragraphs below.
Seeking Alpha • Aug 07

Peeking Back In On Paratek Pharmaceuticals

The stock of Paratek Pharmaceuticals has fallen since we last took an in-depth look at this antibiotic company in March. Most of this is due to weakness in the sector. The company continues to make solid progress, and its shares are far below analyst firm price targets. A full and independent investment analysis follows in the paragraphs below.
Articolo di analisi • Mar 01

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) is possibly approaching a major achievement in its business, so we would...
Articolo di analisi • Feb 01

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) can tell us which group is most powerful...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Evan Loh rispetto agli utili di Paratek Pharmaceuticals?
DataCompenso totaleStipendioUtili della società
Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$650k

-US$64m

Sep 30 2022n/an/a

-US$89m

Jun 30 2022n/an/a

-US$86m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$4mUS$600k

-US$59m

Sep 30 2021n/an/a

-US$52m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$2mUS$575k

-US$97m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$111m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$2mUS$520k

-US$129m

Sep 30 2019n/an/a

-US$124m

Jun 30 2019n/an/a

-US$124m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$2mUS$480k

-US$112m

Sep 30 2018n/an/a

-US$111m

Jun 30 2018n/an/a

-US$101m

Mar 31 2018n/an/a

-US$89m

Dec 31 2017US$3mUS$450k

-US$89m

Sep 30 2017n/an/a

-US$94m

Jun 30 2017n/an/a

-US$96m

Mar 31 2017n/an/a

-US$108m

Dec 31 2016US$1mUS$415k

-US$112m

Compensazione vs Mercato: La retribuzione totale di Evan ($USD 2.04M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 630.36K ).

Compensazione vs guadagni: La retribuzione di Evan è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Evan Loh (64 yo)

4.3yrs
Mandato
US$2,042,511
Compensazione

Dr. Evan Loh, M.D., FACC, FAHA, has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 25, 2019. Dr. Loh served as Independent Director at Windtree Therapeutics, Inc. since Februa...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director4.3yrsUS$2.04m1.87%
$ 2.4m
Adam Woodrow
President & Chief Commercial Officer4.3yrsUS$1.15m1.09%
$ 1.4m
Sarah Higgins
VP of Finance8.5yrsNessun datoNessun dato
William Haskel
Senior VP8.3yrsUS$1.25m0.62%
$ 797.8k
Jonathan Light
Deputy General Counsel & Chief Compliance Officer6.1yrsNessun datoNessun dato
Karen McGrath
Chief People Officer4.2yrsNessun datoNessun dato
Randall Brenner
Chief Development & Regulatory Officer4.3yrsNessun dato0.58%
$ 735.2k
4.3yrs
Durata media
58.5yo
Età media

Gestione esperta: Il team dirigenziale di PRTK è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director11.3yrsUS$2.04m1.87%
$ 2.4m
Jeffrey Stein
Lead Independent Director8.9yrsUS$147.80k0.097%
$ 124.0k
Thomas Dietz
Independent Outside Director8.9yrsUS$150.30k0.087%
$ 111.5k
Kristine Peterson
Independent Outside Director7.5yrsUS$137.80k0.10%
$ 131.6k
Timothy Franson
Independent Outside Director8.2yrsUS$135.30k0.10%
$ 131.6k
Robert Radie
Independent Outside Director8.9yrsUS$140.30k0.091%
$ 116.5k
Rolf Hoffmann
Independent Director5.4yrsUS$127.80k0.11%
$ 142.7k
Minnie Baylor-Henry
Independent Director2.3yrsUS$132.80k0.068%
$ 87.4k
8.9yrs
Durata media
64yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PRTK sono considerati esperti (durata media dell'incarico 8.9 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2023/09/22 02:24
Prezzo dell'azione a fine giornata2023/09/20 00:00
Utili2023/06/30
Utili annuali2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Paratek Pharmaceuticals, Inc. è coperta da 11 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Michael UlzBaird
Jason Matthew GerberryBofA Global Research
Timothy ChiangBTIG